Cabaletta Bio (CABA) - News Mentions

Sign up to add (CABA) to your portfolio and access more historical data.

10%
Est. daily news mentions.

Sign up to access historical data

Sign up

Similar companies

Company News Mentions
Amgen
Amgen
AMGN		 1 0%
Gilead Sciences
Gilead Sciences
GILD		 0 0%
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals
CPRX		 0 0%
Inovio Pharmaceuticals
Inovio Pharmaceuticals
INO		 0 0%
Anavex Life Sciences
Anavex Life Sciences
AVXL		 0 0%
State Street Corp Sells 1,109,678 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA)
December 30
Brokerages Set Cabaletta Bio, Inc. (NASDAQ:CABA) Target Price at $24.38
December 26
Cabaletta Bio (NASDAQ:CABA) Cut to “Inline” at Evercore ISI
December 22
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 71,876 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA)
December 17
XTX Topco Ltd Acquires 72,638 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA)
December 16
Cabaletta Bio, Inc.'s (NASDAQ:CABA) latest 25% decline adds to one-year losses, institutional investors may consider drastic measures
December 9
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Recommendation of “Buy” from Analysts
December 4
Weekly Analysts’ Ratings Updates for Cabaletta Bio (CABA)
December 2
Cabaletta Bio to Participate in Upcoming Investor Conferences in December
November 25
Cabaletta Bio (NASDAQ:CABA) Discloses Promising Clinical Data from ACR Convergence 2024 ConferenceOn November 18, 2024, Cabaletta Bio, Inc. released pivotal information from the American College of Rheumatology (ACR) Convergence 2024 conference. The
November 20
Cabaletta Bio’s (CABA) “Outperform” Rating Reiterated at William Blair
November 19
Wells Fargo & Company Cuts Cabaletta Bio (NASDAQ:CABA) Price Target to $12.00
November 18
Cabaletta Bio (NASDAQ:CABA) Receives Buy Rating from HC Wainwright
November 17
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
November 17
Cabaletta Bio stock hits 52-week low at $3.47 amid market challenges
November 15
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
November 13

Month over Month

Est. daily news mentions.

Dec 2024 0
Nov 2024 0
Oct 2024 0
Sep 2024 0
Aug 2024 0

How often is Cabaletta Bio mentioned in the news?

Cabaletta Bio was mentioned an estimated 1 times in online prominent news articles yesterday.

Analyzing News Mentions, how is Cabaletta Bio performing compared to its industry peers?

Cabaletta Bio underperforms its industry peers when it comes to News Mentions, ranking in the 33rd percentile.

Has there been an increase or decrease in news mentions of Cabaletta Bio in the last month?

There has been no significant change in the number of news mentions for Cabaletta Bio's compared to the last month.

Why is it important to track news mentions for Cabaletta Bio?

By monitoring mentions in the news for Cabaletta Bio, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of Cabaletta Bio, ultimately improving their investment strategies.

Sign up and get more insights on Cabaletta Bio.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2025 AltIndex. All rights reserved.

Top Stocks

Trending Stocks
Trending Stocks on WallStreetBets
Trending Stocks on Reddit
Top Stocks
Top Stock Performers Today
Bottom Stock Performers Today
Best Airlines Stocks
Best Bank Stocks
Best Semiconductor Stocks
Best Energy Stocks
Best Fintech Stocks
Best Robotics Stocks
Best Insurance Stocks

Our Data

Datasets
Stock alerts
AI Stock Picks
AI Stock Picks - Results
Fear & Greed Index
Meme Stocks
Threads Users
Stock Predictor
Stock Picking Reviews
Stock Trading Signals
House & Congress Trading
Earnings Calendar
Index

AltIndex

News
Pricing
Sign up
Log in
API
Journalist Access
Data Disclaimer
Contact